Residency · Residency · Nephrology

Chronic Kidney Disease - Progression and Management

Introduction

Chronic kidney disease affects approximately 15 percent of the US adult population, corresponding to roughly 37 million people, with a global prevalence of 10 to 13 percent. CKD is independently associated with cardiovascular disease, hospitalization, and all-cause mortality. The leading causes of ESRD are diabetic kidney disease at approximately 45 percent, hypertension at 25 percent, glomerulonephritis at 10 percent, and polycystic kidney disease at 5 percent. CKD is often asymptomatic until advanced stages, making early detection and intervention critical for slowing progression.

Definition and Staging

KDIGO 2012 Classification

CKD is defined as abnormalities of kidney structure or function present for more than 3 months, encompassing either a GFR below 60 mL/min/1.73m2 for more than 3 months or markers of kidney damage including albuminuria, urine sediment abnormalities, electrolyte or tubular disorders, histologic abnormalities, structural abnormalities on imaging, or a history of kidney transplant.

GFR Categories

Albuminuria Categories

Risk Stratification (Heat Map)

Prognosis in CKD is determined by the combination of GFR and albuminuria categories, producing a risk stratification heat map. Green indicates low risk for combinations such as G1-2/A1. Yellow represents moderate risk for G1-2/A2 and G3a/A1. Orange denotes high risk for G3a/A2 and G3b/A1. Red signals very high risk for G3b/A2-3 and all G4-5 categories regardless of albuminuria.

Mechanisms of CKD Progression

Common Pathway of Progression

Regardless of the initial insult, CKD progression follows a shared final pathway. Nephron loss triggers compensatory hyperfiltration in remaining nephrons, as described by the Brenner hypothesis. The resulting glomerular hypertension with increased single-nephron GFR subjects podocytes to mechanical stress, leading to proteinuria and mesangial sclerosis. Filtered proteins activate proximal tubular cells, stimulating chemokine and cytokine production that drives interstitial inflammation and fibrosis. Tubulointerstitial fibrosis represents the common endpoint and correlates most strongly with GFR decline. RAAS activation perpetuates the cycle through angiotensin II-driven fibrosis via TGF-beta, inflammation, and hemodynamic injury. Capillary rarefaction with loss of peritubular capillaries produces chronic hypoxia that further promotes fibrosis.

Modifiable Risk Factors

Proteinuria is the strongest modifiable predictor of CKD progression. Additional modifiable risk factors include hypertension, hyperglycemia in diabetic kidney disease, smoking, obesity, high sodium diet, nephrotoxin exposure, and recurrent episodes of acute kidney injury.

Non-Modifiable Risk Factors

Non-modifiable risk factors include age, sex, race and ethnicity, genetic factors such as APOL1 variants, PKD, and Alport syndrome, and low nephron endowment from prematurity, low birth weight, or intrauterine growth restriction.

<image>Diagram illustrating the common pathway of CKD progression. Start with initial kidney injury (any cause) leading to nephron loss. Show the vicious cycle: nephron loss → compensatory hyperfiltration in remaining nephrons → increased intraglomerular pressure → podocyte injury and proteinuria → tubular protein overload → proximal tubular activation and cytokine release (MCP-1, TGF-beta, CTGF) → interstitial inflammation → myofibroblast activation → tubulointerstitial fibrosis → capillary rarefaction → chronic hypoxia → further nephron loss. Include intervention points where drugs act: RAAS blockade (reduces intraglomerular pressure), SGLT2 inhibitors (reduce hyperfiltration via TGF), finerenone (blocks MR-mediated inflammation and fibrosis), and GLP-1 RA (anti-inflammatory, metabolic effects). Show proteinuria as the central driver connecting glomerular injury to tubulointerstitial fibrosis.</image>

Evidence-Based Interventions to Slow Progression

RAAS Blockade

ACE inhibitors and ARBs have been the cornerstone of CKD management for more than 20 years. Their benefits include reduction of intraglomerular pressure, decrease in proteinuria by 30 to 50 percent, and slowing of GFR decline, as demonstrated in key trials including RENAAL, IDNT, REIN, and AASK. These agents should be titrated to the maximum tolerated dose. Clinicians should accept up to a 30 percent rise in serum creatinine as a hemodynamic effect and manage hyperkalemia with dietary restriction and potassium binders. The combination of ACE inhibitor plus ARB should not be used, as ONTARGET and VA NEPHRON-D demonstrated harm without benefit.

SGLT2 Inhibitors

SGLT2 inhibitors are now considered foundational therapy for CKD with or without diabetes. The DAPA-CKD trial demonstrated a 39 percent reduction in the renal composite, with benefit in both diabetic and non-diabetic CKD. The EMPA-KIDNEY trial showed a 28 percent reduction, including patients with an eGFR of 20 to 45 regardless of albuminuria. These agents can be initiated at an eGFR of 20 mL/min or above and continued until dialysis or transplant. Their benefits extend beyond hemodynamic effects of tubuloglomerular feedback restoration to include anti-inflammatory and anti-fibrotic properties.

Finerenone (Non-Steroidal MRA)

The FIDELIO-DKD and FIGARO-DKD trials demonstrated renal and cardiovascular benefit of finerenone in type 2 diabetes with DKD. The indication is currently limited to type 2 diabetes with CKD, though trials in non-diabetic CKD are ongoing.

GLP-1 Receptor Agonists

The FLOW trial demonstrated that semaglutide reduced the renal composite by 24 percent in type 2 diabetes with DKD, providing benefits through glycemic control, weight loss, cardiovascular risk reduction, and direct renal effects.

Blood Pressure Control

The SPRINT trial demonstrated a 27 percent reduction in cardiovascular events and 25 percent reduction in all-cause mortality with an intensive systolic blood pressure target below 120 mmHg compared to the standard target below 140 mmHg. KDIGO 2021 recommends a target below 120 mmHg systolic for non-diabetic CKD based on SPRINT. For diabetic CKD, a target of less than 130/80 mmHg is recommended, as ACCORD-BP showed no additional benefit of targeting below 120 in diabetic patients. Office blood pressure may overestimate the true level, and confirmation with ambulatory or home blood pressure monitoring is recommended.

Proteinuria Reduction

The target for proteinuria reduction is less than 0.5 to 1 gram per day or a UACR below 300 mg/g. RAAS blockade and SGLT2 inhibitors achieve additive proteinuria reduction. Dietary sodium restriction to less than 2 grams per day enhances the antiproteinuric effect of RAAS blockade. Sparsentan, a dual endothelin A and angiotensin II type 1 receptor antagonist, provides additional antiproteinuric effect in IgA nephropathy as demonstrated in the PROTECT trial.

Metabolic Acidosis Correction

Serum bicarbonate below 22 mEq/L is associated with faster CKD progression. The UBI trial demonstrated that oral sodium bicarbonate supplementation to maintain bicarbonate above 22 mEq/L slowed eGFR decline. KDIGO recommends treating to maintain serum bicarbonate at 22 mEq/L or above. Treatment options include sodium bicarbonate 650 to 1300 mg three times daily or sodium citrate (Shohl solution). Veverimer (TRC101), a non-absorbed polymer that binds hydrochloric acid in the gastrointestinal tract, has completed phase III trials and is under FDA review.

Dietary Interventions

Sodium restriction to less than 2 grams per day enhances RAAS blockade, reduces proteinuria, and improves blood pressure control. Moderate protein restriction to 0.8 g/kg/day is recommended for CKD stages G3 through G5 not on dialysis, based on the MDRD study which showed modest benefit with low protein diet. Plant-based protein may offer advantages over animal protein due to lower acid load and lower phosphorus bioavailability. Potassium intake should be individualized, avoiding excessive restriction unless hyperkalemia is present, as potassium-rich diets are associated with better CKD outcomes in observational studies.

<image>Comprehensive management framework for CKD showing evidence-based interventions organized by the four pillars of treatment. Pillar 1: Hemodynamic (RAAS blockade with ACEi/ARB, SGLT2 inhibitor, BP target <120 systolic for non-DM or <130/80 for DM). Pillar 2: Metabolic (glycemic control HbA1c 6.5-7.5%, metabolic acidosis correction with NaHCO3 to maintain bicarb ≥22, lipid management with statin). Pillar 3: Anti-inflammatory/Anti-fibrotic (finerenone for DKD, GLP-1 RA for DKD, SGLT2i pleiotropic effects). Pillar 4: Lifestyle (sodium <2g/day, protein 0.8 g/kg/day, smoking cessation, exercise, weight management). For each intervention, show the key trial name and the magnitude of benefit (% risk reduction). Include eGFR thresholds for drug initiation and a timeline for monitoring (BMP, UACR, CBC every 3-6 months).</image>

CKD Complications Management

Cardiovascular Disease

Cardiovascular disease is the leading cause of death in CKD, with a 10 to 30-fold higher risk compared to the general population. The SHARP trial demonstrated a 17 percent reduction in major atherosclerotic events with simvastatin plus ezetimibe in CKD, with benefit across all CKD stages. KDIGO recommends statin therapy for all CKD patients aged 50 years or older and for CKD G1-4 patients aged 18 to 49 with additional risk factors. Aspirin should be considered for secondary prevention, though there is no clear benefit for primary prevention in CKD. For anticoagulation in atrial fibrillation, direct oral anticoagulants are preferred over warfarin for patients with an eGFR of 25 to 50, with dose adjustment based on eGFR. Data remain limited for rivaroxaban and apixaban at eGFR below 25.

Volume Management

Loop diuretics are preferred for volume management when eGFR falls below 30, as thiazides become less effective at this level, though chlorthalidone may retain efficacy. The CLICK trial demonstrated that chlorthalidone remained effective for blood pressure reduction in CKD G4 with an eGFR of 15 to 29. Diuretic resistance can be managed by increasing the loop diuretic dose, adding a thiazide for sequential nephron blockade, and reinforcing dietary sodium restriction.

Medication Dose Adjustment

All renally cleared medications require dose adjustment based on eGFR. Common adjustments include metformin which should be stopped at an eGFR below 30, direct oral anticoagulants, gabapentin and pregabalin, allopurinol, and antibiotics. Drug references such as Lexicomp and clinical pharmacist consultation should be utilized.

Preparation for Renal Replacement Therapy

Timely Referral

Nephrology referral is recommended when eGFR falls below 30, per KDIGO guidelines, with earlier referral indicated for rapid decline, difficult-to-manage complications, or diagnostic uncertainty. Late referral within 3 months of dialysis initiation is consistently associated with worse outcomes, higher hospitalization rates, and increased mortality.

Pre-Dialysis Education

Modality education should cover all available options including in-center hemodialysis, home hemodialysis, peritoneal dialysis, and preemptive transplantation. Shared decision-making is essential, and conservative management without dialysis is appropriate for some elderly patients with multiple comorbidities.

Access Planning

Arteriovenous fistula creation should be planned by referral to vascular surgery when eGFR reaches 15 to 20, allowing 6 to 12 months for maturation. Peritoneal dialysis catheter placement can be performed 2 to 4 weeks before starting PD. Transplant evaluation should begin when eGFR falls below 20, and living donor transplant can be performed preemptively before dialysis initiation.

Conservative Management

Conservative management without dialysis is appropriate for patients with poor prognosis, multiple comorbidities, or personal preference. This approach focuses on symptom management, quality of life, and end-of-life care planning. Median survival without dialysis in elderly patients over 75 with an eGFR below 10 is approximately 6 to 12 months, though this varies widely.

Key Clinical Pearls

• The four pillars of CKD progression prevention are now: RAAS blockade, SGLT2 inhibitor, BP control, and lifestyle modification; finerenone and GLP-1 RA add further benefit in DKD
• Proteinuria is the strongest modifiable predictor of CKD progression; every intervention should be assessed by its impact on proteinuria reduction
• An initial eGFR dip of 10-30% after starting ACEi/ARB or SGLT2i is hemodynamic and protective; it should NOT prompt discontinuation unless the decline exceeds 30% or hyperkalemia develops
• SPRINT changed BP targets in CKD: systolic <120 mmHg is the target for most non-diabetic CKD patients; measure with automated oscillometric devices (manual readings are higher)
• Timely nephrology referral, vascular access planning, and modality education are critical for optimizing the transition to RRT; late referral is consistently associated with worse outcomes

References

1. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2024;14(4):S1-S314.
2. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). N Engl J Med. 2020;383(15):1436-1446.
3. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-2116.
4. Baigent C, Landray MJ, Reith C, et al. The Effects of Lowering LDL Cholesterol with Simvastatin plus Ezetimibe in Patients with Chronic Kidney Disease (SHARP). Lancet. 2011;377(9784):2181-2192.
5. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy (RENAAL). N Engl J Med. 2001;345(12):861-869.

Read this lecture as Markdown